佛慈制藥(002644.SZ):公司股票將於10月27日起復牌
格隆匯10月26日丨佛慈制藥(002644.SZ)公佈。公司於2023年9月21日披露了甘肅省國有資產投資集團有限公司(以下簡稱"甘肅國投"、"收購人")出具的《蘭州佛慈制藥股份有限公司要約收購報吿書》(以下簡稱"《要約收購報吿書》"),收購人甘肅國投向公司除蘭州佛慈醫藥產業發展集團有限公司(以下簡稱"佛慈集團")以外的所有股東所持有的上市流通普通股(A股)發出全面要約收購。本次要約收購股份數量為195,943,324股,佔公司總股本的38.37%。要約收購價格為9.55元/股,收購期限為2023年9月22日起至2023年10月23日止。
2023年9月22日至2023年10月23日要約收購期限內,最終有66個賬户,共計4,083,860股股份接受收購人發出的要約。
公吿顯示,收購人甘肅國投通過購買佛慈集團100%股權的方式成為其控股股東,收購佛慈集團能夠充分發揮甘肅國投國有資本投資和運營功能,通過統籌規劃、資源整合和專業化運營,構建甘肅省中醫藥全產業鏈條,提升隴藥產值和市場份額。
佛慈集團為上市公司佛慈制藥的控股股東,持有上市公司已發行股份的61.63%。本次交易完成後,甘肅國投通過佛慈集團間接擁有佛慈制藥的權益將超過佛慈制藥已發行股份的30%,從而觸發全面要約收購義務。因此,根據《證券法》和《收購管理辦法》,甘肅國投應當向佛慈制藥除佛慈集團之外的其他所有持有上市流通普通股(A股)的股東發出全面要約。本次要約收購不以終止佛慈制藥的上市地位為目的。
此外,公司股票將於2023年10月27日(星期五)開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.